pamrevlumab pamrevlumab pamrevlumab (inn; development code fg-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. it binds to the connective tissue growth factor (ctgf) protein. pamrevlumabmonoclonal antibodytype?sourcehumantargetctgfclinical dataother namesfg-3019atc codenoneidentifierscas number946415-13-0chemspidernoneuniiqs5f6vts0okeggd10969chemical and physical dataformulac6492h10018n1718o2086s48molar mass147050.38 g·mol−1 this drug was developed by fibrogen, inc.